Off-Label Policy: History And Legal Basis
This article was originally published in RPM Report
Here is the “background” section from FDA’s March draft guidance on reprint distribution. The section includes more than 20 footnotes (omitted here) that reflect an effort by FDA to update and buttress the legal basis for the prohibition on off-label promotion.
You may also be interested in...
Stephen Hahn’s low visibility period as the newly installed FDA commissioner comes to an abrupt end. Trump offers generous praise amid COVID-19 response – but how quickly might that change to blame?
Final phase overhaul of FDA's new drug review groups includes half-a-dozen first-time division directors. Most have long experience at the agency – but not all with the drugs they will now oversee.
If the President says over and over again that a drug is approved, does that make it so?